<DrugInformationSummary id="CDR0000801930"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This targeted therapy combination consists of two monoclonal antibodies, pertuzumab and trastuzumab, and hyaluronidase-zzxf, a recombinant form of a naturally occurring enzyme. Pertuzumab and trastuzumab bind to different parts of the HER2 protein on the surface of some cancer cells, causing the cells to stop growing and die. Both also trigger a type of immune reaction that kills cells that have a lot of HER2. Hyaluronidase-zzxf makes it easier for the body to absorb these targeted therapies. 
</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/pertuzumabtrastuzumabandhyaluronidase-zzxf">Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000801876">pertuzumab, trastuzumab, and hyaluronidase-zzxf</TerminologyLink><GlossaryLink ref="CDR0000801883">pertuzumab, trastuzumab, and hyaluronidase</GlossaryLink><USBrandNames><USBrandName>Phesgo</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>per-TOO-zoo-mab tras-TOO-zoo-mab … HY-al-yoo-RAH-nih-days</TermPronunciation><MediaLink ref="CDR0000804382" type="audio/mpeg" alt="" language="en" id="_5"/><MediaLink ref="CDR0000804383" type="audio/mpeg" alt="" language="es" id="_6"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Pertuzumab, trastuzumab, and hyaluronidase-zzxf
         is approved to be given with <GlossaryTermRef href="CDR0000045382" dictionary="Cancer.gov" audience="Patient">docetaxel</GlossaryTermRef> or other chemotherapy to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">Breast cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000737998" dictionary="Cancer.gov" audience="Patient">HER2 positive</GlossaryTermRef>. It is used:<ItemizedList Style="bullet" id="_4"><ListItem>with chemotherapy as <GlossaryTermRef href="CDR0000045800" dictionary="Cancer.gov" audience="Patient">neoadjuvant therapy</GlossaryTermRef> (to shrink the tumor before surgery) in adults with <GlossaryTermRef href="CDR0000045955" dictionary="Cancer.gov" audience="Patient">locally advanced</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045313" dictionary="Cancer.gov" audience="Patient">inflammatory</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000446564" dictionary="Cancer.gov" audience="Patient">early-stage breast cancer</GlossaryTermRef></ListItem><ListItem>with chemotherapy as <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef> in adults with early-stage breast cancer who have a <GlossaryTermRef href="CDR0000045079" dictionary="Cancer.gov" audience="Patient">high risk</GlossaryTermRef> that their cancer will <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recur</GlossaryTermRef> (come back)</ListItem><ListItem>with the chemotherapy drug docetaxel in adults with <GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">metastatic</GlossaryTermRef> breast cancer that has not been treated with anti-HER2 therapy or chemotherapy</ListItem></ItemizedList></ListItem>
   </ItemizedList>
  <Para id="_5">Pertuzumab, trastuzumab, and hyaluronidase-zzxf is a fixed-<GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">dose</GlossaryTermRef> <GlossaryTermRef href="CDR0000688810" dictionary="Cancer.gov" audience="Patient">combination</GlossaryTermRef> of <GlossaryTermRef href="CDR0000340934" dictionary="Cancer.gov" audience="Patient">pertuzumab</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045439" dictionary="Cancer.gov" audience="Patient">trastuzumab</GlossaryTermRef> that is given as a <GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneous</GlossaryTermRef> <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injection</GlossaryTermRef>. It can be given in less time than pertuzumab or trastuzumab, which are given as <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusions</GlossaryTermRef>. For more information about pertuzumab and trastuzumab that may apply to pertuzumab, trastuzumab, and hyaluronidase-zzxf, see the Drug Information Summaries for <DrugRef href="CDR0000735473" url="/about-cancer/treatment/drugs/pertuzumab">Pertuzumab</DrugRef> and <DrugRef href="CDR0000502211" url="/about-cancer/treatment/drugs/trastuzumab">Trastuzumab</DrugRef>.</Para>
 </Section><Section id="_About"><Title>More About Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/801876">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.27">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a620048.html">Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.28"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.29">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C173339">Find Clinical Trials for Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2020-07-15</DateFirstPublished><DateLastModified>2024-12-20</DateLastModified></DrugInformationSummary>
